Efficacy and safety of one intravitreal injection of bevacizumab in diabetic macular oedema.

摘要: PURPOSE To assess the efficacy, duration of effect and safety one intravitreal injection bevacizumab in diabetic macular oedema (DMO). METHODS Bevacizumab (1 mg/0.04 ml) was injected intravitreally into eyes with DMO (29 nine without previous treatments). Best corrected visual acuity (BCVA), intraocular pressure central retinal thickness (CRT) were measured; slit-lamp examination, biomicroscopy, optical coherence tomography fluorescein angiography performed before at 2-4, 8 12 weeks post-injection. VA CRT analysed both groups. RESULTS In non-pretreated group, mean BCVA improved from 0.76 +/- 0.33 (baseline) to 0.57 0.30 0.54 0.27 2-4 post-injection, respectively (p = 0.02, p 0.014, paired t-test). Mean decreased 632.4 196.0 microm 392.3 113.6 370.4 141.7 same time-points, 0.01, 0.01). There no difference or weeks. pretreated 0.62 0.53 post-injection 0.01), 583.9 180.7 404.1 197.9 < 0.001). unchanged although remained lower 0.004). No ocular systemic side-effects developed during follow-up. CONCLUSIONS One for seems be effective safe that have been treated previously not. The therapeutic is temporary repeat treatment may needed.